drugset / Trial / NCT03684278
Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial (RAPID-I)
Phase 2
Recruiting
240 enrolled
University of Liverpool
Bangor University · collabLiverpool University Hospitals NHS Foundation Trust · collabMedical Research Council · collabMerck Sharp & Dohme LLC · collabNational Institute for Health Research, United Kingdom · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study evaluates the effectiveness and safety of infliximab in the treatment of acute pancreatitis in adults. A third of participants will receive one single dose of infliximab via infusion, another third will receive a higher dose of infliximab via infusion and the final third of participants will receive a placebo infusion.
Timeline
- Start
- 2019-05-01
- Primary completion
- 2026-12-15
- Completion
- 2027-03-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Infliximab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Comparator | Infliximab | Monoclonal antibody | 10 mg/kg | Intravenous |